Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Overview of attention for article published in Advances in Therapy, August 2019
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (90th percentile)
-
High Attention Score compared to outputs of the same age and source (92nd percentile)
Mentioned by
- news
- 1 news outlet
- 4 X users
- patent
- 1 patent
- guideline
- 2 clinical guideline sources